News | July 27, 2021
Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
The US business faced price erosion due to increased competition.
The US business faced price erosion due to increased competition.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
Sun Pharma has committed Rs. 100 crores towards these initiatives
Subscribe To Our Newsletter & Stay Updated
